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Abstract
Oxidative stress-related diseases underlie many if not all of the major leading causes of death in 
United States and the Western World. Thus, enormous interest from both academia and 
pharmaceutical industry has been placed on the development of agents which attenuate oxidative 
stress. With that in mind, great efforts have been placed in the development of inhibitors of 
NADPH oxidase (Nox), the major enzymatic source of reactive oxygen species and oxidative 
stress in many cells and tissue. The regulation of a catalytically active Nox enzyme involves 
numerous protein-protein interactions which, in turn, afford numerous targets for inhibition of its 
activity. In this review, we will provide an updated overview of the available Nox inhibitors, both 
peptidic and small molecules, and discuss the body of data related to their possible mechanisms of 
action and specificity towards each of the various isoforms of Nox. Indeed, there have been some 
very notable successes. However, despite great commitment by many in the field, the need for 
efficacious and well-characterized, isoform-specific Nox inhibitors, essential for the treatment of 
major diseases as well as for delineating the contribution of a given Nox in physiological redox 
signalling, continues to grow.
Keywords
NADPH oxidase; Nox; inhibitors; peptides; small molecules; therapeutics
INTRODUCTION
ROS and Disease
Oxidative stress is implicated as a common underpinning in hypertension [1], cancer [2], 
diabetes [3], ischemia reperfusion injury [4], neurodegenerative disorders such as 
Alzheimer’s and Parkinson’s disease [5] to name a few. As these diseases underlie many if 
not all of the major leading causes of death in United States [6], and the Western World, 
enormous interest from both academia and pharmaceutical industry, has been placed on the 
development of agents which attenuate oxidative stress. This attenuation can be either via 
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the agent’s role as antioxidants or as inhibitors of enzymatic sources implicated in altering 
the redox state within cells and tissues. Oxidative stress is a term describing a shift towards a 
pro-oxidative cell or tissue state whereby reactive oxygen (ROS) and nitrogen species (RNS) 
overwhelm antioxidant defense mechanisms. The latter serve to (a) scavenge excessive ROS 
and repair attendant damage by such excess; and/or (b) maintain reduced (GSH)/oxidized 
(GSSG) glutathione ratios responsible to preserve adequate reducing equivalents for overall 
cell function as well as key antioxidant and non-antioxidant enzymes. While multiple 
enzymatic sources are capable of generating ROS, a wide consensus in the literature accepts 
that the NADPH (nicotinamide adenine dinucleotide phosphate) oxidase (Nox) family are 
major “professional” producers of ROS and linked to the aforementioned and many other 
pathologies [1,2,5,7–17] An extensive discussion of the important roles of ROS from a 
variety of other subcellular sources can be found in more comprehensive reviews elsewhere 
[1,18,19].
Nox Enzymes
NADPH oxidases (Noxs) are considered “professional” ROS-producing enzymes as their 
primary, defined function is the generation of superoxide and/or hydrogen peroxide (H2O2) 
via the controlled transfer of electrons from NADPH to molecular oxygen by way of flavin 
adenine dinucleotide (FAD)-binding and NADPH-binding sites on the enzymes’ C-terminal 
tail. Importantly, the Nox family of functionally- and structurally-related enzyme systems is 
comprised of seven members; namely Nox1 through 5 and DUOX1 & 2. Interestingly, these 
isoforms differ in their tissue distribution, level of expression, nature of ROS produced, and 
control by distinct signaling modulators. Of these, Nox2, which is present in neutrophils and 
macrophages, was the first to be discovered [20,21] and is the most thoroughly characterized 
isoform. As the structure, localization and activation mechanisms for the Nox family 
members have been the subject of numerous in-depth reviews, [4,22] they will not be 
mentioned in detail here, except to give the reader a deeper perspective of the complexity of 
interactions required for a fully functional enzyme. This perspective will then inform the 
reader of the wide variety of strategic interventions that are plausible for Nox inhibition.
All Nox isoforms are characterized by a catalytic core, consisting of a bis-heme-containing 
transmembrane domain (6 – 7) and a C-terminal intracellular dehydrogenase tail that carries 
the required sites for FAD and NADPH binding. p22phox, a membrane-bound component 
present in Nox1-, Nox2, Nox3 and Nox4 complexes (but not in those of Nox5, Duox1 or 
Duox2), stabilizes its Nox counterpart and serves as a docking site for other regulatory 
subunits depending on the particular Nox system. [23]. These other regulatory subunits can 
act as organizers (targeting other subunits to the membrane) or as activators (directly 
modulating catalytic activity). The active Nox2 oxidase system comprises the Nox2 subunit 
and p22phox(membranal) as well as cytosolic p47phox (organizer), p67phox(activator), 
p40phox and the small Rho-family GTP-binding protein Rac2 and also Rac1 [24,25]. 
Similarly, the active Nox1 system is comprised of membrane-bound Nox1 and p22phox and 
in its generally accepted, canonical complex, of organizing subunit NoxO1 (homolog of 
p47phox), activating subunit NoxA1 (homologue of p67phox), and Rac1 [26]. Increasing 
evidence supports a non-canonical-Nox1 system which utilizes p47phox, in lieu of NoxO1, 
for activation [27] in vascular smooth muscle cells. As it is for Nox1, evidence supports the 
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notion that the rodent Nox3 oxidase system requires NoxO1, NoxA1, and Rac1 besides its 
core membranal Nox3 and p22phox subunits [28] while human Nox3 has been reported to be 
activated by NoxO1 alone [29]. On the other hand, p47phox and p67phox apparently can, in 
certain settings, supplant the role of NoxO1 and NoxA1 in Nox3 oxidase albeit to lesser 
effect [30,31]. To our knowledge, Nox3 expression is restricted to the inner ear and some 
fetal tissues [28]. In contrast, the Nox4 isozyme includes the Nox4 subunit and p22phox, but 
the only other reported protein to our knowledge to modulate its function is Poldip2 [32]. 
Another differential feature of Nox4 is that is reportedly constitutively active and 
preferentially produces H2O2 over superoxide anion [33]. Incidentally, Nox4 has been 
proposed as an oxygen sensor [33]. Nox5 and DUOXs 1and 2 are distinct from Noxs 1 
through 4 as they putatively do not require p22phox for membrane stabilization and are 
regulated by calcium binding to EF-hand motifs present in their N-terminal calmodulin 
homology domains [34–36]. Interestingly, Duox1 and Duox2 have an extra membrane-
spanning domain with a peroxidase-like domain in their extracellular N-terminal region. 
Processing of Duox1 and 2 involving endoplasmic reticulum-to-Golgi transition, maturation, 
and translocation to the plasma membrane requires the presence of DUOXA1 and 
DUOXA2, respectively, to constitute a fully functional H2O2-generating enzyme [37].
As described above, the assembly and regulation of a catalytically active Nox system 
involves numerous protein-protein interactions [38–40]. Depicted in Figure 1 are common 
sites of interaction between the individual components of an active Nox enzyme. In the case 
of the Nox2 isozyme, a key interaction exists between a pro-line-rich domain (PRD) on 
p22phox and the bis-Src Homology 3 (SH3) domains of the organizer p47phox(Fig. 1: #1)
[41,42]. p47phox also interacts with the SH3 domains from the activator p67phox through its 
C-terminal PRD region and through an additional surface, a helix-turn-helix motif, 
downstream from PRD (Fig. 1: #2)) [43–46]. As an organizer, p47phox binds to the C-
terminus of Nox2 through its polybasic region (Fig. 1: #3) [47]. On the other hand, p67phox 
is able to interact with Nox2 C-terminus (Fig. 1: #4) [48,49] and with Rac (Fig. 1: #5) [50]. 
Intramolecular interactions within individual Nox components important for enzymatic 
activity have also been described (Fig. 1: #6). For example, in dormant phagocytes the SH3 
domains of p47phox interact with its auto-inhibitory region (AIR) [42,51]. This 
intramolecular interaction blocks the SH3 domains’ interaction with other subunits. It is only 
upon serine phosphorylation by protein kinase C that these SH3 domains are unmasked and 
enzyme activation proceeds. In the case of the canonical Nox1 system, similar protein-
protein interactions have been demonstrated for NoxO1 and p22phox. However, the 
interaction between NoxO1 and NoxA1 were shown to be significantly different from that 
between their homologous subunits in Nox2 in that the surface of interaction between both 
proteins seems to have lower affinity and to involve only the helix-turn-helix motif of 
NoxO1 interacting with the SH3 domain of NoxA1 [52]. This difference may offer insight 
into functional differences between the Nox1 and 2 isoforms. In addition, Yamamoto et al., 
demonstrated that interaction of NoxO1 and NoxA1 is further regulated by phosphorylation 
of T341 of NoxO1 that in turn increases Nox1 activity [53]. Intramolecular interactions 
within NoxO1 are also distinct from its counterpart, p47phox. That is, NoxO1’s auto-
inhibitory potential at its C-terminal region is less pronounced, which may allow for the 
observed higher basal Nox1-derived superoxide anion generation [52]. Intramolecular 
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interactions within the Nox anchoring subunits have also been described for Nox4 and Nox2 
in which the polybasic region in the second intracellular loop, loop B, putatively binds to the 
DH-domain linking the heme-binding transmembrane domain with the FAD- and NADPH-
binding domains. Thus, it is proposed that this intramolecular folding facilitates electron 
transfer and superoxide anion production [54]. In the case of Nox5, whose B-loop does not 
contain a polybasic region, the intramolecular interaction involves region in the EF-hands 
domain and a regulatory EF-hand-binding domain within the DH domain [55].
Finally, protein-protein interactions between the membrane-spanning subunits have also 
been described (Fig. 1: #7). For example, Ambasta et al., using fluorescence resonance 
energy transfer techniques, demonstrated that p22phox forms complexes with Nox1, Nox2, 
and Nox4 disrupted by mutation of histidine 115 [56]. Differential interactions between 
Nox4 and p22phox have also been shown by mutation analysis [57]. Notwithstanding the 
need for specific Nox enzyme inhibitors for diseases in which oxidative stress is a causative 
factor, Nox isozymes have emerged as pivotal to homeostatic redox signaling. Thus, a better 
understanding of the aforementioned interactions is expected to provide key insight into 
modalities to “tweak” Nox activity in the positive or negative sense. Indeed, Noxs play an 
important role in signal transduction, i.e. participating in pathways including ERK1 and 
ERK2, NF-kB, JNK, and others leading to salutary and/or compensatory phenotypes 
[58,59]. Our growing appreciation of Noxs modulating fundamental physiological processes 
has shed important new light on the complex yet elemental significance of this oxidase 
family of enzymes [60].
History of Nox Inhibitors
Our understanding of the contribution of any given Nox isoform to a specific signaling 
pathway has been limited by the lack of isoform-selective inhibitors. The utility of inhibitors 
to gain insight into NADPH oxidase functionality was realized early in the discovery of the 
respiratory burst enzyme, now known as Nox2 oxidase [61,62]. Among the first Nox 
inhibitors to appear in the literature in the late 1980s through the 1990s were small molecule 
iodonium compounds [63,64], apocynin [65], AEBSF [66], S17834 [67], and the peptidic 
inhibitors PR-39 [68]. Soon thereafter, a first-in-class Nox inhibitor was designed to 
specifically inhibit Nox2 [69,70] and named gp91ds-tat, now named Nox2ds-tat, which will 
be discussed in more detail below. At the time of introduction of these early inhibitors to the 
field, other members of the Nox family had yet to be identified. Thus, it is not surprising that 
more thorough investigations of their mechanism of action and specificity since have in most 
cases revealed significant off-target effects.
Some of the characteristics of those early inhibitors have been reviewed previously [71–77]. 
The advent of the discovery of a 7-member family of NADPH oxidases ushered in an 
urgency to find selective inhibitors of each isozyme, be they peptidic or small molecule. It is 
the goal of this review to survey the literature and categorize each identified inhibitor by its 
effects on individual Nox enzymes and perhaps better appreciate the need for isoform 
specificity.
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PEPTIDIC NOX INHIBITORS
The more information that is obtained in terms of the key regulatory regions for assembly 
and activation of the Nox protein and its specific subunits, the more rationally peptidic 
inhibitors can be designed. Below we describe a few promising peptidic inhibitors available 
to date with special emphasis on those which exemplify strategies for inhibition of activity 
and exploit defining characteristics of each of the target enzymes (Fig. 2). Importantly, some 
of these strategies include peptides replicating amino acid sequences within the Nox subunit 
itself, which are pivotal for the assembly of active enzyme (Fig. 2A). Others include 
peptides derived from one of the cytosolic subunits required for activity (Fig. 2B), and 
peptides mimicking regions within the Nox subunit and key to processes such as auto-
inhibition (Fig. 2C). Fundamentally, these rationally-designed inhibitors take advantage of 
intrinsic regulatory interactions of the Nox.
Inhibitors of Nox2
A wealth of information has been amassed over the years by the Pick, Jesaitis and Quinn 
laboratories on the structure and mechanisms associated with Nox2 activation. This is 
attributable largely to the development of peptidic inhibitors, many of which were identified 
using phage display[78,79] and peptide walking [80,81]. A wide spectrum of peptides 
capable of inhibiting Nox2 activity in vitro has been identified based on sequences from 
Nox2 or p47 phox proteins or from p22phox sequences and tested with respect to Nox2 
activity [82]. A small subset of these peptides has been characterized in terms of their 
specificity and await testing of their effectiveness in vitro and in vivo. For detailed analysis 
of these peptides, please refer to outstanding reviews by El-Benna and coworkers [83,84].
PR-39—An endogenous proline-arginine (PR)-rich antibacterial peptide, PR-39 (RRR 
PRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP), was first described as an inhibitor of 
Nox2 based on the knowledge that the assembly of phagocyte NADPH oxidase required 
protein-protein interactions between SH3 domains of one and proline-rich domains (PRDs) 
of other Nox subunits. In fact, as shown by Shi et al. [68], PR-39 inhibited phagocytic Nox2 
in whole cells and in cell-free preparations presumably by binding to SH3-domain in 
p47 phox and interfering with its binding to the PRDs within the C-terminus of p22phox. 
Indeed, PR-39 exerted cardioprotective effects following ischemia reperfusion which often 
involves activation of Nox [85]. However, further analysis demonstrated that this peptide 
could bind to other proteins besides p47phox, including other SH3-containing proteins, 
p130Cas [86] and PI3Kp85α [87]. Thus, careful interpretation of the results obtained using 
PR-39 is required and its use as a Nox2 inhibitor is recommended with consideration of 
potential off-target effects.
Nox2-Based Peptides—A thorough study by Dahan et al. [88] employing peptide 
walking analysis within the dehydrogenase region of Nox2 identified 10 clusters of 
inhibitory peptides that, in turn, helped to define ten functional domains in the C-terminal 
region of Nox2. Two of these domains, 288FWRSQQKVVITKVVT302 (cluster A) 
and 312MKKKG FKMEVGQYIF326 (cluster B), are found in the N-terminal region of Nox2 
dehydrogenase domain. One, 348EDFFSIHIRIVGDWT362 (cluster C), in the ribityl chain-
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binding FAD subdomain. Four clusters overlapped portions of three NADPH-binding 
subdomains, that is peptides 393TASEDVFSYEVVMLV407 (cluster D) and 414TPFAS 
ILKSVWYKYC428 (cluster E) located to the pyrophos -phate-binding subdomain, 
while 432TNLKLKKIYFYWLCR446 (cluster F) and 528PNTRIGVFLCGPEAL542 (cluster 
H) contain residues required for the binding of ribose and nicotinamide moieties of NADPH, 
respectively. Cluster F1 (447DTHAFEWFA455) is contiguous to Cluster F, so it probably 
participates also in the binding of the ribose moiety. Peptide 468RNNAGFLSYNIYLTG482 
(cluster G) corresponds to a region of unknown functional importance. 
Peptide 552SNSESGPRGVHFIFN566 (cluster I) was located in the C-terminal region of the 
enzyme and overlaps with a peptide previously described as binding to p47phox[47]. 
Interestingly, the pep-tides corresponding to FAD- and NADPH-binding regions did not 
exhibit the expected competitive kinetics regarding their respective substrates and were also 
able to inhibit enzymatic activity when added after complex assembly, suggesting a more 
complex mechanism of action. The validity of these peptides as isoform-specific Nox2 
inhibitors remains to be determined since they primarily target regions involved in catalysis 
shared by all members of the Nox family.
Nox2ds-tat—Nox2ds-tat, designed in our laboratory, appears to distinguish itself from 
other peptide inhibitors as the only isoform-selective Nox inhibitor currently available. 
Nox2ds-tat was designed based on data from random-sequence peptide phage display 
showing that peptides corresponding to the B-loop of the Nox2 catalytic core, a short loop 
between helix 2 and 3, exhibited inhibitory activity in cell-free activity assays [79].
This together with the knowledge of a small 9-aa peptide derived from the HIV viral coat 
(HIV-tat) [89] capable of delivering conjugated proteins across membranes, gave rise to the 
design of an 18-mer chimeric peptide, Nox2ds-tat (originally named gp91ds-tat) [70] 
(sequence above; for mechanism of action see Fig. 2A). To date, Nox2ds-tat having been 
used in an array of experimental models to investigate the role of Nox2, appears to be the 
best characterized and most widely-used Nox2-selective inhibitor in the field. From the 
outset, this peptide was shown to be highly efficacious at inhibiting Nox2-derived ROS in 
vitro as well as in vivo [70,90,91] and from then on has been employed in a range of cell and 
animal models of disease. The ROS-generating stimuli that can be blocked by Nox2ds-tat 
include nutrient deprivation [92], hypoxia [93] atrial natriuretic peptide [94] angiopoietin-1 
[95], interleukin-4 [96], shear stress [97], calcineurin inhibitors [98], endothelin-1 [99], 
TNF-α [100], and phenylephrine [101] to name a few. Nox2ds-tat also blocked angiotensin 
II (AngII)-induced superoxide production in human resistance artery smooth muscle cells 
[102] and collagen-induced Nox2 activity in platelets [103]. Furthermore, Nox2ds-tat has 
been applied to elucidate the involvement of Nox2 in various processes leading to function 
and dysfunction of various organ systems, e.g. hypertension [104], diabetes [14], retinopathy 
[93], Alzheimer’s disease [105] and aging [106]. Importantly, the specificity of Nox2ds-tat 
was rigorously tested utilizing heterologous cell-free systems expressing the classical Nox2 
(p22phox, Nox2, p47phox, and p67phox), canonical Nox1 (p22phox, Nox1, NOXA1, and 
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NOXO1), or Nox4 (p22phox and Nox4) oxidases, as well as the non-canonical Nox1 
(p22phox, Nox1, p47phox, and NoxA1) system [107]. The findings demonstrated that 
Nox2ds-tat inhibits the canonical Nox2 system, but not Nox1 (canonical or non-canonical) 
or Nox4-derived ROS production. The IC50 calculated for Nox2 inhibition was 0.74µM, thus 
demonstrating that Nox2ds-tat is a moderately potent, efficacious, and selective inhibitor of 
Nox2. The mechanism of action of Nox2dstat seems to involve binding to p47phox as shown 
by enzyme-linked immunosorbent assay using biotinylated peptide [107].
Inhibitors of Nox1
NoxA1ds—In the past two years another isoform-specific inhibitor of Nox was developed, 
in this case the targeted enzyme being Nox1 [108]. NoxA1ds (NoxA1 docking sequence) is 
a peptide that mimics a putative activation domain of the human Nox1 activator subunit 
NOXA1 homologous to a reported p67phox activation domain that spans amino acids 199–
210 and participates in the catalytic reduction of FAD [48].
With the knowledge that mutagenesis of a tyrosine for an alanine at residue 199 of NoxA1 in 
a region corresponding to the defined “activation domain” of its homolog p67phox reduced 
Nox1-derived superoxide production by >95% [109], it was postulated that the same 
substitution would render a peptide as an effective inhibitor of Nox1 activity. To confer 
specificity, amino acids flanking this putative activation domain (that were not conserved 
between NOXA1 and p67phox) were included. NoxA1ds potently inhibited Nox1-derived 
ROS production in a reconstituted, heterologous Nox1 cell-free system (IC50 = 19 nM), 
displaying no inhibitory effect on Nox2-, Nox4-, Nox5-, or xanthine oxidase activity [108]. 
Further, FRET, FRAP, and competitive binding analyses were consistent with NoxA1ds 
eliciting its effect by binding to Nox1 and thus blocking its interaction with NoxA1 (Fig. 
2B). NoxA1ds significantly inhibited whole HT-29 carcinoma cell-derived ROS and 
hypoxia-induced human pulmonary artery endothelial cell ROS production and migration 
[108]. It seems likely, although it has not been tested, that the unmutated NoxA1 peptide 
could have an inhibitory effect on Nox1 activity. Recently, in an attempt to define the sites of 
interaction between Nox1 and NoxA1, Streeter et al. [110] used a NoxA1-AD peptide 
(LEPMDFLGKAKVV) which corresponds to the rat sequence overlapping NoxA1ds and 
showed interaction of NoxA1 with T429-phosphorylated Nox1 using computational 
modeling. In that study, NoxA1-AD peptide showed higher affinity to a phosphorylated form 
of a Nox1 peptide (KLKTQKIYF) at T429 compared to its non-phosphorylated counterpart.
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Inhibitors of Nox4
Elegant studies by the Knaus and Lambeth laboratories supported key interactions in the 
Nox4 complex that could be exploited as targets [54,57]. A systematic screening of synthetic 
peptides, encompassing various regions on Nox4 protein including B-loop and C-terminus, 
as well as peptides mimicking p22phox regions thought to be essential for activity, yielded no 
inhibitor for Nox4. Thus, similar strategies to those used for peptidic inhibitors of Nox1 and 
2 did not prove successful [111]. Those results could suggest that Nox4 exists in a tightly-
assembled and active conformation which, unlike other Noxs, cannot be disrupted by 
conventional means.
Inhibitors of Nox5
In contrast to Nox1, 2, 3 and 4, Nox5 does not require other membrane-associated or 
cytosolic activator proteins for its activity [34,112] but its activation is mediated by an 
increase in cytosolic Ca2+ concentration acting on EF-hand motifs.
Pep1 and Pep3—In an attempt to investigate how the N-terminal region of Nox5 
containing the EF domain, interacts with its C-terminal catalytic dehydrogenase domain 
(CDHD) leading to activation of the enzyme, Tirone et al. [55] were able to narrow the site 
of interaction to a region between two NADPH binding sites in the C-terminal portion of 
Nox. Interestingly, specific peptides (Pep1 and Pep3) targeting this regulatory calcium-
binding domain of NOX5 were capable of blocking Ca2+-dependent superoxide generation 
in a dose-dependent manner (IC50 = 30 µM).
It is noteworthy that Pep2 and Pep4 interacted very weakly or not at all with the Nox5-EF 
domain, as evidenced by pull-down assays, despite the fact that they overlapped 
substantially with Pep1 or Pep3. In fact, Pep4 and Pep1 differ by only 5 amino acid residues, 
emphasizing the importance of the KDSIT stretch for Nox5-EF/CDHD interaction [55]. 
Although the inhibitory activity of Pep1 and 3 was only tested in Nox5 activity assays, it is 
not expected that they would block the activity of other Noxs due to (a) the absence of EF-
hands; and (b) poor homology of aligned corresponding sequences for Nox 1, 2, 3, and 4 to 
that of Nox5. Still, direct testing of specificity remains to be performed. Purportedly, these 
peptides may represent a site in the catalytic domain of Nox5 that has an auto-inhibitory role 
[55] (Fig. 2C).
Melittin—Melittin is a 26 amino acid peptide (GIGAVLKVLTTGLP ALISWIKRKRQQ) 
derived from bee venom that has demonstrated potent Nox5 inhibition displaying an IC50 of 
101 nM. The binding was shown to be Ca2+-dependent and it seems to act through direct 
binding with the EF-hand domains [112]. Melittin, however, is not specific to Nox5 but also 
binds to other Ca2+-dependent proteins such as calmodulin and troponin C [113].
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Inhibitors of Nox3, DUOX1 and 2
To our knowledge, no peptidic inhibitors have yet been developed to specifically target Nox3 
or DUOX1 and 2.
Afterthoughts
Despite the general potential for specific targeting and effectiveness of biological inhibitors, 
such as peptides, few have entered the clinical pipeline thus far, and none of those are Nox 
inhibitors [114,115]. The use of peptides as potent inhibitors of enzymatic activities raises 
concerns, mainly due to the preconceived notion that peptides lack therapeutic potential due 
to poor oral bioavailability, gut degradation, and toxicity. However, as Dahan & Pick [116] 
elegantly submit, those limitations can be minimized by strategic design and identification of 
appropriate sequences. Then, optimization of peptide ADME (absorption, distribution, 
metabolism, and excretion) properties and means of delivery could circumvent the 
limitations and improve therapeutic use [117]. Some examples of these attempts include 
peptide modifications that provide protection from protease degradation by stapling or 
partial substitution of L-amino acids with their D-isomers [118,119]. In terms of targeted 
peptide delivery, unpublished studies by our group targeting pulmonary diseases, indicate 
that aerosolization of NoxA1ds directly into the nasal passages and lungs, markedly reduces 
right ventricular hypertrophy in rodent models of pulmonary hypertension.
SMALL MOLECULE INHIBITORS
Selective, potent, and efficacious inhibition of Nox isozymes remains a major challenge in 
the discovery of small molecules with potential for progress towards therapeutic 
development. As our understanding of the Nox enzymes improves, we anticipate multiple 
methods of inhibition will become available, thereby opening the door to different classes of 
inhibitors, for example, catalytic core manipulation versus protein assembly inhibition. In 
contrast to peptidic inhibitors the strategy used to identify small molecule inhibitors is 
usually less borne out of rational targeting of protein-protein interactions than it is the high 
throughput screening of small molecules libraries. This requires a careful and thoughtful 
workflow of specific assays and counter screens to select the most specific hits [76,120]. 
Once a hit is identified, random modification of elements of the parent molecule may be 
pursued. Increased use of computational modeling facilitates the rational design of lead 
molecules.
Inhibitors of Nox2
The first group of compounds initially identified as Nox2 inhibitors using a high throughput 
screening strategy were the Vaso-pharm triazolo pyrimidine derivatives, VAS2870 [121] and 
VAS3947 [122]. Interestingly, VAS2870 inhibited superoxide production from cell-free 
Nox2 containing neutrophil system with an IC50 of 10.6 µM [121] and completely abolished 
oxLDL-induced Nox-derived ROS in human umbilical vein endothelial cells (HU-VECs) at 
10 µM [123]. Moreover, the more soluble VAS3947 showed efficacy similar to that of 
VAS2870 in cell-based assays [122]. That said, the VAS compounds are now commonly 
regarded as pan-Nox inhibitors due to their ability to completely inhibit ROS production in 
multiple agonist-induced cell models with varied Nox expression [124,125]. Structurally, 
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VAS compounds share a central nucleotide core and it is therefore predicted that these 
compounds interact at the level of nucleotide binding, i.e. NADPH or FAD. This would, in 
fact, explain their lack of isoform specificity and also their ability to inhibit the pre-
assembled Nox2 [126]. Recent report have shed light on the negative aspects of using 
VAS2870 as a Nox inhibitor, demonstrating off-target effects through thiol alkylation [127] 
and inhibition of mitochondrial respiration and cytotoxicity [120]. More detailed binding 
and mutagenesis assays are required to fully elucidate the mode of inhibition of VAS 
compounds for Nox2.
Another group of compounds suggested to possess Nox2 inhibiting capabilities are the 
pyrazolopyrimidine compounds [128]. This group of molecules inhibited Nox activity in 
bovine aortic endothelial cell membrane fractions with an IC50 < 1 µM and inhibited 
extracellular superoxide formation by intact PMA-stimulated human neutrophils [126]. 
However, the authors also noted that these compounds failed to produce a decrease in Nox2-
derived superoxide in a reconstituted neutrophil system. Consequently, the mechanism of 
reduced ROS generation was demonstrated via potent inhibition of protein kinase C (PKC)-
βII, a key regulator of p47 phox phosphorylation. Thus, until further information becomes 
available, the use of pyrazolpyrimidine compounds as Nox2-targeted inhibitors should be 
discouraged.
Previously, the triterpenoid celastrol [129] originally referred to as an “antioxidant” was 
demonstrated to potently inhibit both Nox1-derived ROS (IC50 = 0.41 ± 0.20 µM) and 
Nox2-derived ROS (IC50 = 0.59 ± 0.34 µM) following PMA stimulation [130]. While the 
efficacy for both the canonical Nox1 and Nox2 systems was greater than the non-canonical 
Nox1 and 2 systems, the mode of inhibition is demonstrated as disrupting interaction of the 
proline rich region of p22phox and the tandem SH3 domains of either p47 phox or NoxO1. 
Structure-activity relationship (SAR) analogues are anticipated to generate a new class of 
competitive Nox inhibitors acting specifically at the level of p47phox-p22phox vs. NoxO1-
p22phox interface. Whether this potential new class of compounds would discriminate 
between Nox1 vs Nox2 is still unknown.
A new group of Nox2 inhibitors identified to competitively inhibit the p47phox-p22phox 
binding interface are ebselen and its analogues. These compounds were identified utilizing a 
fluorescence polarization-based binding assay [131], as well as traditional ROS read-out 
assays. Importantly, this line of inquiry provides a rigorous methodology for the 
investigation of potential compounds impinging on protein-protein interactions. In the initial 
study, ebselen and some of its analogs were documented as potent Nox2 inhibitors which 
affected Nox1, 4, and 5 activities at a substantially lower potency depending upon the 
congener [131]. One derivative, JM-77b, had a selectivity for Nox2 (IC50= 0.4 µM) 
compared to Nox1 (IC50= 6.3 µM), Nox5 (IC50= 17 µM), and Nox4 (no significant 
inhibition) [131]. This class of compounds appears to hold significant promise for selective 
Nox2 inhibition. Mindful of ebselen’s reported glutathione peroxidase-like activity [132], 
congeners of ebselen found to be devoid of this activity should be of considerable interest.
Naloxone, a commonly-used antagonist of opioid receptors, was previously characterized as 
highly effective in preventing dopaminergic degeneration in different models of rodent 
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Parkinson’s disease by inhibiting inflammation [133]. Importantly, it was shown that 
naloxone binds to Nox2 and blocks translocation of p47 phox to the plasma membrane, thus 
inhibiting ROS generation [134]. Naloxone’s IC50 was in the range of 2µM and inhibited the 
activity of the pre-assembled Nox2 enzyme [134]. However, no reports could be found 
disproving its binding or inhibition of other Nox subunits. Similarly, perhexiline, an 
approved prescription drug for angina, was recently demonstrated to inhibit neutrophilic 
Nox2 with an IC50 of 1.5–3.6 µM as well as in various vascular cells [135]. Importantly, 
perhexiline displayed no scavenging ability or xanthine oxidase inhibition. Its mechanism of 
action and its effect on other Nox isoforms requires further investigation.
Our group recently identified bridged tetrahydroquinolines as specific Nox2 inhibitors based 
on cellular assays employing heterologous Nox1,Nox2, Nox4, and Nox5 expressing systems 
[136]. In this report, compounds 11g and 11h showed selective inhibition of Nox2 in intact 
Cos-Nox2 cells stimulated with PMA (IC50 = 20 ± 1.9 and 32 ± 1.9 µM, respectively). 
Importantly, these compounds were unable to inhibit ROS production by Nox1-, Nox4-, and 
Nox5-expressing cells and exhibited no free radical scavenging or xanthine oxidase 
inhibitory activity. Although limited mechanistic information exists pertaining to their mode 
of inhibition within the current scientific literature, unpublished work employing modeling 
suggests a potential role as assembly inhibitors, acting on the p47phox-p22phox interface. 
That said, there is still considerable work to be done in the way of SAR to enhance potency, 
minimize potential off-target effects, and hence tissue and whole animal toxicity. 
Nevertheless, we contend that compounds 11g and 11h hold significant promise as prototype 
selective small molecule inhibitors of Nox2.
Inhibitors of Nox1
Given the promiscuous nature of the Nox1 oxidase as a canonical- or non-canonical-Nox1 
system which utilizes p47phox, small molecule inhibitors intended for the canonical Nox2, 
p47phox-dependent enzyme could have effects on the non-canonical-Nox1 system (e.g. 
celastrol and ebselen derivatives) [75]. In that regard, a deeper understanding of the Nox1 
activation process and potential distinct p47phox interactions with Nox1 versus Nox2 would 
be advantageous.
ML171 (2-acetylphenothiazine) belongs to a subset of phenothiazines and has an IC50 for 
Nox1 in the submicromolar range from cell-based assays, namely 0.129 µM in HT29 cells 
and 0.25 µM in a HEK293-Nox1 reconstituted cell system [137]. Moreover, the specificity 
of ML171 for other Noxs was reportedly >20-fold higher for Nox2, −3, and 4 as well as for 
xanthine oxidase compared to Nox1[137]. Importantly, the suggested mechanism of action 
surrounding ML171 was interaction with Nox1 catalytic subunit as only over-expression of 
Nox1, and not NoxA1 nor NoxO1, was able to restore the ML171-dependent inhibition of 
ROS generation in HEK293-Nox1-expressing cells [137]. However, by the same reasoning, 
ML171’s potential effect as an allosteric inhibitor of Nox1 at a region distinct from the 
catalytic site could also have been superseded by Nox1 overexpression.
A high-throughput screening (HTS) approach of small molecule libraries and subsequent 
optimization of lead compounds enabled the identification of dual Nox1/4 inhibitors by 
GenKyoTex (GKT) [138,139]. Among these compounds are GKT136901 and GKT137831, 
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which belong to a pyrazolopyridine class of compounds, and are the first orally-active dual 
Nox1 and 4 inhibitors [140–142]. The first compound, GKT136901, was found to be a Nox 
inhibitor with a relatively high degree of potency for both Nox4 (inhibitory constant (Ki) = 
165 ± 5 nM) and Nox1 (Ki =160 ± 10 nM). Similarly, the second compound, GKT137831, 
was shown to be a highly potent inhibitor of both human Nox4 (Ki =140 ± 40 nM) and 
human Nox1 (Ki=110 ± 30 nM). Indeed, these compounds are in phase II trials for the 
treatment of diabetic nephrophathy, which based on animal models, is thought to involve 
Nox4 but not Nox1[143]. One potential cause for concern is that Nox4 has been implicated 
broadly in cell differentiation and physiologic redox signaling and the drug may have 
deleterious effects in non-diseased organs. Additionally, GKT compounds were 
demonstrated to be a viable therapeutic for the treatment of idiopathic pulmonary fibrosis 
and liver fibrosis, both diseases with implicated Nox4 and/or Nox1 contributions [138,140]. 
GKT compounds are to date the best-characterized small molecule Nox inhibiting 
compounds, having been subjected to extensive in vivo screening analysis for off target 
effects, reportedly having favorable ADME profiles as well as being orally bioavailable 
[138,140]. It is expected that the mechanism of action of the GKT compounds could involve 
catalytic core modulation due to the lack of extensive protein assembly in Nox4 (see below). 
GKT compounds only exhibit 10–15-fold higher selectivity for Nox1/4 than Nox2. 
Therefore, consideration of the administration of high doses (>50mg/kg) in vivo [141] 
should be taken as these could obviate selectivity.
As alluded to previously, the inhibitors VAS2870 and VAS3947, considered pan-Nox 
inhibitors, are able to inhibit Nox-derived ROS production in multiple agonist-induced cell 
models.. Consequently, as with the GKT compounds, VAS compounds may interact at the 
level of nucleotide binding due to their lack of isoform specificity and also their ability to 
inhibit the pre-assembled Nox [126]. Further, ebselen and analogues are also predicted to 
inhibit Nox1-derived superoxide, especially when the non-cano-nical-Nox1 system is 
present or the agonist used favors p47phox-dependent Nox1 activation. In a similar vein, 
celastrol, being a recognized assembly inhibitor acting at the level of p47phox/NoxO1 and 
p22phox, potently inhibits Nox1-derived superoxide anion as discussed above.
Inhibitors of Nox3
The current biochemical literature surrounding the activation process of Nox3 remains 
limited. Moreover, the current dogma for cytosolic subunit preference and interchangeability 
of p47 phox for NoxO1 and p67phox for NoxA1 in Nox3 activation renders creation of protein 
assembly inhibitors a challenge. Thus, it is anticipated that the p47phox/NoxO1 class of 
assembly inhibitors e.g. celastrol and ebselen derivatives, could have an effect on Nox3. To 
date, no specific small molecule inhibitors to our knowledge exist for Nox3-dependent 
superoxide production despite its role in balance regulation, otoconia biosynthesis, and 
potentially hearing loss [28]. However, one report did identify a novel synthetic compound, 
3-amino-3-(4-fluorophenyl)-1H–quinoline-2,4-dione (KR-22332) that significantly inhibited 
cisplatin-induced intracellular ROS generation in vitro and was protective against cisplatin-
induced hearing loss in a rat model involving Nox3 ROS production [144]. Since no 
biochemical analysis or modeling was performed, it is not clear if these effects were elicited 
via catalytic inhibition or by other means. Furthermore, ML171 is also able to inhibit Nox3-
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dependent superoxide with an IC50 of 3 µM [137]; and further studies are required to 
determine the effects of other currently-available Nox inhibitors on the Nox3 system. Taken 
together, it is not outside the realm of possibilities that drugs that were designed or screened 
for other Noxs will exhibit an interesting profile of Nox3 inhibition.
Inhibitors of Nox4
To date, Nox4 transcriptional expression remains the most accepted mechanism for 
increased Nox4-derived ROS in cells and tissues [145,146]. Importantly, the interaction 
between Nox4 and p22phox appears to be tightly regulated as peptidic inhibitor strategies 
failed to affect Nox4 activity [111]. Despite this observation, a number of currently available 
inhibitors are reported to potently and effectively attenuate Nox4-derived ROS although 
often via unspecified mechanisms. As mentioned previously (for more detail, see Nox1 
section) GKT compounds represent the first orally-available phase-II clinical trial candidates 
as dual Nox1/4 inhibitors for the treatment of diabetic nephropathy promoted in rodent 
models by Nox4 [147]. Emerging evidence, however, implicates Nox5 in human 
glomerulopathies [148]. These compounds also decrease angiogenesis and tumor volume, 
and improve diabetes-accelerated atherosclerosis, for which Nox1 vs. Nox4 are attributed, 
respectively [149,150].
Similarly, VAS3947, ML171 and celastrol exhibit Nox4 inhibition at higher concentrations 
than their intended Nox1 & 2 targets (see Table 1). Previously, triphenylmethane dyes, such 
as brilliant green and gentian violet, which have chemical characteristic resembling DPI, 
were shown to be potent and efficacious inhibitors of both Nox2 and Nox4 activity [151]. 
Therefore, from a structure-based approach, fulvene and its derivatives were generated as a 
new class of Nox2/4 inhibitors. Importantly, fulvene-5 at 5 µM equally inhibited Nox2 and 
Nox4 in vitro, and when applied in vivo, successfully blocked the growth of endothelial-
mediated tumors in mice [152]. However, since the process of tumor angiogenesis is 
suggested to be a Nox4-driven mechanism, most likely it is the ability of fulvene-5 to inhibit 
Nox4 that confers its efficacy in vivo. This contention is buttressed by studies showing Nox4 
shRNA produces similar effects [152]. That being said, fulvenes should be classified as 
putative inhibitors until which time a mechanism of action is identified and their possible 
role as scavengers can be ruled out. Finally, the recently-identified diarylheptanoid group of 
compounds obtained from edible plants yielded a compound named ACD084, which 
inhibited Nox4 with an IC50 of 3 µM without inhibition of either Nox2 or Nox5 [153]. 
Moreover, while other diaryl-heptanoids inhibited Nox4-derived ROS, they also were also 
capable of inhibiting Nox2. However, limited scavenging analysis was performed on the 
identified compounds and the authors reportedly did not investigate the effects on Nox1-
derived superoxide. While mechanistic information is lacking for the mode on Nox4 
inhibition by ACD084, it is predicted to interfere with nucleotide binding given its ability to 
inhibit ROS production from purified Nox4-dehydrogenase domain samples [153]. It 
remains to be determined whether this could also be true for the other Nox isoforms.
Inhibitors of Nox 5 & DUOXs 1 & 2
Recently, Nox5 has emerged as an attractive target for the development of inhibitors because 
of its potentially distinct and complicating role in humans. The inability to study this 
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isozyme in rats and mice has greatly limited experimental inquiry. However, with enhanced 
procurement and study of human clinical samples, Nox5 is rapidly being viewed as an 
important ROS source in multiple disease settings. Its regulation by calcium binding and EF-
hand domains also offers opportunities for new interventions. As with all Nox family 
members, Nox5 activity is inhibited by the nonselective flavoprotein inhibitor DPI and ROS 
generated by Nox5 can be partially suppressed with apocynin; however, this effect of 
apocynin could be a direct result of scavenging [154]. Ca2+-dependent Nox5 superoxide 
production has also been shown to be inhibited by GKT136901 in spermatozoa (Ki = ~450 
nM; cells in which Nox1 or Nox4 are not detectable [155]), and by GKT137831 in cell free 
assay of Nox5-overexpressing cells [139]. Furthermore, celastrol was also shown to inhibit 
Nox5-derived superoxide in Nox5-expressing cells (IC50 of 3.13 µM) and purified 
membranes containing Nox5 (IC50 of 8.4 µM) [130]. That said, the associated inhibitory 
mechanisms are yet to be revealed. Incidentally, Nox5 contains structural domains not 
present in other members of the Nox family. We therefore anticipate that a target approach 
for its modulation is plausible; for example, melittin (see peptidic inhibitors section) through 
interactions with Nox5-EF-hands provides a potential site for small molecule Nox5 
inhibition [112]. Similar to Nox5, DUOX1 and DUOX2 enzymes are regulated by calcium 
but require the presence of maturation subunits DUOXA1 or DUOXA2, respectively [37], 
and their role in disease and immunity is an emerging area. Accordingly, the modulation of 
DUOX1/2-derived ROS could prove to be an important area of research; however, to date, 
no known inhibitors of DUOX1/2 exist. Finally, DUOX1/2 enzymes also have EF-hand 
regions and, thus like Nox5, could be inhibited by EF-hand-binding small molecules or 
peptides such as melittin.
SUMMARY & LIMITATIONS
The current body of biochemical and medical literature augurs the need for efficacious Nox 
inhibitors and therapies. Importantly, we, like many others in the field, maintain that isoform 
selectivity is essential for disease treatment as well as its practical implications in 
delineating the contribution of a given Nox in physiological redox signaling. The demand 
for well-characterized, isoform-specific inhibitors including pharmacokinetic and 
pharmacodynamic profiles is yet to be adequately met. As shown in Table 1, it has becomes 
quite evident that data for even the most promising Nox inhibitors is, for the most part, 
incomplete as no compounds to our knowledge have been tested against the full array of 
Nox isozymes. Even the few compounds that have IC50s lower by 10–20-fold for a given 
Nox over other family members should be used mindfully in vivo where appropriate doses 
are more difficult to calibrate. Moreover, considerably more work is required to investigate 
mechanism of action. It is also noteworthy that Nox3, as well as Duox1 and Duox2 remain 
poorly characterized Nox targets. This is apparently a consequence of a greater intensity and 
interest in Noxs in mammalian cardiovascular physiology and disease to this point, where 
knowledge of these particular isoforms is limited or lacking. The established role of Nox3 
and the Duoxs in important physiological functions, e.g. hearing and thyroid function, is also 
likely to be an impediment. In conclusion, the purpose and promise of both peptidic 
inhibitors and a handful of small molecules, each with its own advantages and limitations, 
has grown substantively in recent years and is only expected to burgeon further as interest in 
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the Nox field widens. One promising step in the right direction would be employment of 
detailed information that peptide inhibitors provide in terms of protein-protein interactions 
and use of these as pharma-cophores for the design of stable and bioavailable small 
molecules [156].
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Fig. (1). 
Sites of interaction among Nox subunits.
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Fig. (2). 
Mechanism of action of peptidic inhibitors.
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